Viemed Healthcare (VMD) Q1 Net Margin Stays Near 5% And Tests Bullish Profit Narratives
Viemed Healthcare (VMD) reported Q1 2026 revenue of US$75.4 million and EPS of US$0.07, maintaining a net margin near 5%. While the company has seen 21.2% trailing earnings growth, its steady quarterly EPS and reliance on government reimbursement for a significant portion of its revenue raise questions about its long-term profitability and ability to significantly increase its margins. The article discusses both bullish and bearish perspectives on VMD's valuation and profit trajectory, noting its 22x P/E is below peers and industry averages, with a DCF fair value significantly higher than its current share price.
Viemed Healthcare: Maintaining 'Buy' Rating Post Q1 On Improving Capital Efficiency
Viemed Healthcare (VMD) continues its strong performance, with shares increasing by 28% since January. This growth is fueled by a 28% surge in Q1 revenues to $75.41 million, exceeding expectations, and a raised 2026 revenue guidance to $312-$320 million. The company's strategic shift towards less capital-intensive services is enhancing capital efficiency and supporting sustainable free cash flow generation.
viemed healthcare, inc Earnings dates
This article provides the upcoming earnings date for Viemed Healthcare, Inc. (VMD.V), scheduling its Q3 earnings release for November 6, 2025, after market close. It also includes other recent business headlines and economic updates.
Viemed Healthcare stock (US92671H1068): Q1 earnings update and long?term growth drivers
Viemed Healthcare recently reported its Q1 2026 earnings, posting an EPS of approximately $0.06, which fell short of some market expectations but still indicated positive profitability. The company, specializing in home-based respiratory care, continues to focus on recurring revenue from ventilator rentals and respiratory therapy services. While facing margin pressures from growth investments, Viemed benefits from structural demand drivers like an aging population and a shift towards home-based care, though regulatory risks and competitive pressures remain key factors for investors to monitor.
Behavioral Patterns of VMD and Institutional Flows
This article analyzes the behavioral patterns and institutional flows for Viemed Healthcare Inc. (NYSE: VMD), indicating a positive near-term sentiment that may overcome a weak mid-term bias within a long-term strong trend. It highlights an exceptional 35.0:1 risk-reward setup targeting an 11.7% gain with only 0.3% risk. The analysis also provides AI-generated trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Viemed Healthcare, Inc. - Common Shares (NQ: VMD)
This article provides recent news headlines and press releases concerning Viemed Healthcare, Inc. (NASDAQ: VMD). It covers financial results announcements, earnings call details, analyst coverage updates by Stonegate Capital Partners, share repurchase programs, and conference presentations.
Viemed Healthcare Shows Improved Revenue Mix and Free Cash Flow in Q1 2026
Viemed Healthcare (NASDAQ: VMD) reported strong Q1 2026 results, indicating an improved revenue mix and significant growth in free cash flow. The company is successfully shifting away from traditional ventilator rentals towards higher-growth areas like sleep, resupply, and maternal health, leading to better capital efficiency. This strategic shift has positively impacted its financial performance, with free cash flow rising to $36.3 million.
Viemed Healthcare Shows Improved Revenue Mix and Free Cash Flow in Q1 2026
Viemed Healthcare (NASDAQ: VMD) reported strong Q1 2026 results, showing an improved revenue mix with growth in sleep, resupply, and maternal health services. This shift has led to better free cash flow conversion, with cash flow from operations increasing to $8.1 million and trailing twelve-month free cash flow rising to $36.3 million. The company's strategic focus on less capital-intensive areas is positively impacting its financial performance.
Viemed sleep patients up 57% as ventilator revenue share falls
Stonegate Capital Partners updated its coverage on Viemed Healthcare (NASDAQ: VMD) following its 1Q26 performance, noting stronger free cash flow and a strategic shift in revenue mix. The company saw significant growth in sleep and resupply patient numbers, with PAP patients up 57% year-over-year, while the reliance on ventilator rentals decreased. Despite ongoing pressure from ventilator turnover, Viemed's diversified approach and improved capital efficiency contributed to a positive outlook.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (VMD) following its Q1 2026 results. The report highlights improving growth quality through increased contributions from sleep, resupply, and maternal health, reducing reliance on ventilation. This shift is driving stronger free cash flow conversion for the company.
Stonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q26
Stonegate Capital Partners has updated its coverage on Viemed Healthcare, Inc. (VMD) following its Q1 2026 results. The report highlights improving growth quality with increased contributions from sleep, resupply, and maternal health services, which are reducing reliance on legacy ventilation and improving capital efficiency. Key takeaways include significantly improved free cash flow conversion and a better revenue mix, with PAP patient growth and new patient starts being clear growth drivers.
Viemed Healthcare Q1 2026 Earnings Call: Complete Transcript
Viemed Healthcare reported strong Q1 2026 results with revenue up 28% year-over-year to $75.4 million, driven by growth in sleep and maternal health segments. PAP therapy patients increased by 57%, and free cash flow significantly improved to $2.6 million. The company raised its full-year 2026 revenue guidance to $312 million-$320 million, expressing confidence in continued growth and increasing capital efficiency.
VMD SEC Filings - Viemed Healthcare Inc 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Viemed Healthcare Inc. (VMD) SEC filings available on Stock Titan. It details the types of filings investors can access, such as 10-K, 10-Q, and 8-K reports, and highlights the AI-generated summaries and analytics provided to help interpret these complex documents. The article also touches on recent significant 8-K disclosures and insider trading activities, making regulatory information more accessible.
Viemed Healthcare, Inc. (VMD) Q1 earnings miss estimates
This article states that Viemed Healthcare, Inc. (VMD) missed its Q1 earnings estimates. No further details are provided in the current content.
Viemed Healthcare, Inc. (NASDAQ:VMD) Q1 2026 Earnings Call Transcript
Viemed Healthcare, Inc. reported strong Q1 2026 results, with revenue up 28% year-over-year to $75.4 million, driven by significant growth in its sleep and maternal health segments. The company highlighted enhanced free cash flow, improved capital efficiency, and strategic diversification away from ventilator revenue dependency. Viemed also updated its full-year 2026 guidance, raising the lower end of its net revenue range to $312 million to $320 million, and reaffirms its adjusted EBITDA outlook.
Viemed Healthcare Down Over 8%, on Pace for Largest Percent Decrease in Almost a Year -- Data Talk
Viemed Healthcare (VMD) stock is currently down over 8%, putting it on track for its largest percentage decrease in nearly a year. This significant drop follows a previous session's gain, where the stock had risen over 5%.
Viemed Q1 2026 slides: 28% revenue growth masks earnings miss
Viemed Healthcare Inc. (NASDAQ:VMD) reported Q1 2026 results with 28% revenue growth but missed analyst expectations for earnings and revenue, leading to a premarket stock decline. The company highlighted strong growth in its sleep therapy and maternal health segments as part of its diversification strategy, alongside solid operating cash flow and a net-debt-free balance sheet. Despite the miss, management reaffirmed full-year guidance and expressed confidence in its strategic initiatives.
Earnings call transcript: Viemed Healthcare’s Q1 2026 results miss forecasts
Viemed Healthcare reported Q1 2026 earnings that missed analyst forecasts, with an EPS of $0.06 against an expected $0.09 and revenue of $75.41 million versus the $77.35 million forecast. Despite a 9.79% premarket stock decline, the company achieved 28% year-over-year revenue growth and a significant improvement in free cash flow, driven by strong performance in its sleep/PAP therapy and maternal health segments. Executives expressed confidence in their diversification strategy and ability to adapt to regulatory changes, while InvestingPro analysis suggests the stock may be undervalued.
Viemed Healthcare (NASDAQ:VMD) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Viemed Healthcare (NASDAQ:VMD) recently announced its quarterly earnings, reporting an EPS of $0.06, which missed the consensus estimate of $0.09 by $0.03. Despite the earnings miss, the company's revenue of $75.41 million slightly surpassed analysts' expectations of $74.40 million. Insider selling activity was noted, with insiders selling 136,802 shares totaling about $1.24 million in the last quarter, yet still retaining 20% ownership of the stock.
Viemed Healthcare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Viemed Healthcare, Inc. announced its earnings for the first quarter ended March 31, 2026. The company reported sales of $75.41 million, an increase from $59.13 million a year ago. However, net income slightly decreased to $2.58 million compared to $2.63 million in the same period last year, resulting in diluted earnings per share of $0.06, consistent with the previous year.
Viemed Healthcare (VMD) Q1 2026 revenue jumps 28% as guidance raised
Viemed Healthcare reported robust growth in Q1 2026, with net revenue increasing 28% year-over-year to $75.4 million and Adjusted EBITDA rising 12% to $14.3 million. The company generated strong operating and free cash flow while also repurchasing shares and reducing debt. As a result of this performance, Viemed raised and narrowed its full-year 2026 revenue guidance to between $312 million and $320 million, reaffirming its Adjusted EBITDA outlook.
Viemed Healthcare (Nasdaq:VMD) - Stock Analysis
Viemed Healthcare (VMD) is currently trading significantly below its estimated fair value with a market cap of US$373.3m. While earnings are forecast to grow by 30.76% annually, the company has seen significant insider selling and has flagged revenue and earnings growth as a major risk due to a 9.7% annual decline over the past five years. Recent reports show mixed financial results, with revenue exceeding expectations but EPS lagging, despite ongoing acquisition plans and share repurchase programs.
Viemed Q1 2026 Results: Revenue Up 28%, Guidance Raised
Viemed Healthcare announced strong financial results for Q1 2026, with net revenues increasing 28% to $75.4 million and adjusted EBITDA up 12% to $14.3 million. The company also raised its full-year 2026 revenue guidance to between $312 million and $320 million, reflecting favorable trends and a more capital-efficient business model. Viemed's CEO highlighted significant growth in sleep and maternal health, along with positive momentum in the ventilator business.
Viemed Healthcare Inc expected to post earnings of 9 cents a share - Earnings Preview
Viemed Healthcare Inc (VMD) is projected to report earnings of 9 cents per share. This financial forecast is provided by Refinitiv in an earnings preview, indicating an upcoming earnings announcement for the company.
Three Insider-Favored Growth Companies With High Ownership
This article highlights three growth companies with high insider ownership in the United States market: Viemed Healthcare (VMD), Ramaco Resources (METC), and Uxin (UXIN). It provides an overview of each company's operations, financial performance, and future growth forecasts, emphasizing that high insider ownership can signal strong internal confidence and alignment with shareholder interests. The article also notes the US market's recent flat performance but significant annual increase and forecasted earnings growth.
Three Insider-Favored Growth Companies With High Ownership
This article highlights three growth companies—Viemed Healthcare (VMD), Ramaco Resources (METC), and Uxin (UXIN)—that exhibit high insider ownership, indicating strong internal confidence. These companies operate in diverse sectors and show significant potential for earnings and revenue growth, despite some facing challenges like net losses or legal issues. The analysis emphasizes the strategic importance of high insider ownership as an alignment of interests with shareholders in a flat market.
Viemed Healthcare (VMD) to Release Quarterly Earnings on Tuesday
Viemed Healthcare (VMD) is scheduled to release its Q1 2026 earnings on Tuesday, May 5th, with analysts expecting $0.09 EPS and $74.4 million in revenue. The company previously beat EPS estimates in the last quarter but slightly missed revenue. Insider selling has occurred recently, with institutional investors holding a significant portion of its stock.
Equity pool at Viemed (NASDAQ: VMD) could reach 20% of shares
Viemed Healthcare, Inc. is calling its 2026 annual general and special meeting to vote on several items, including electing seven directors, ratifying Ernst & Young LLP as auditor, and approving an amendment to its 2024 Long Term Incentive Plan. If approved, the amendment would increase the combined share reserve under current and prior equity plans to 7,696,717 common shares, representing 20% of outstanding shares. This increase would add 913,542 shares for future equity grants, aimed at aligning employee incentives with shareholder interests, though it also expands potential dilution.
Viemed Healthcare Announces Q1 2026 Earnings Call
Viemed Healthcare, Inc. (NASDAQ:VMD) has announced it will host its First Quarter 2026 Earnings Conference Call on Wednesday, May 6, 2026, at 11:00 a.m. EDT. Interested parties can participate via a toll-free number, international number, or a live audio webcast. A replay will also be available on the company's investor relations website.
Viemed Healthcare (NASDAQ:VMD) Stock Price Down 0.8% - Should You Sell?
Viemed Healthcare's stock (NASDAQ:VMD) experienced a 0.8% decline, trading at $9.66 on Monday, with trading volume below average. Despite an earnings per share beat, the company missed revenue expectations. Insider selling has occurred, but Wall Street Zen recently upgraded the stock to a "strong-buy," while the consensus analyst rating remains "Hold."
Viemed Healthcare Inc (NASDAQ:VMD) Identified as a CAN SLIM Growth Candidate
Viemed Healthcare Inc (NASDAQ:VMD) has been identified as a CAN SLIM growth candidate due to its strong financial performance and chart-based signals. The company meets several key criteria of the CAN SLIM method, including significant quarterly and annual earnings growth, strong market leadership, moderate institutional ownership, and a sound financial position. Investors are encouraged to conduct further examination despite the positive filter results.
Viemed Healthcare, Inc. (VMD) Stock Analysis: Exploring A 35% Potential Upside
Viemed Healthcare, Inc. (VMD) is a notable player in the healthcare sector, specializing in home medical equipment and post-acute respiratory services, particularly for COPD patients. The company, currently trading at $9.61 with a market cap of $370.97 million, shows strong financial health with 25.50% revenue growth and an 11.11% return on equity. Technical indicators suggest bullish trends with a potential upside of approximately 35.28% from current levels, targeting an $11.00-$15.00 range, making it attractive for growth-oriented investors despite an absence of analyst ratings.
VIEMED HEALTHCARE INC (NASDAQ:VMD) Passes High-Growth Momentum and Trend Template Screen
VIEMED HEALTHCARE INC (NASDAQ:VMD) has passed a "High Growth Momentum and Trend Template" screen, indicating strong technical uptrends and solid underlying business growth. The company exhibits robust technical indicators, including trading above key moving averages and high relative strength, alongside accelerating fundamental performance in earnings and sales. This combination suggests VMD is a potential leader early in its growth phase, making it an interesting candidate for investors.
Viemed Healthcare Announces Third Quarter 2025 Financial Results
Viemed Healthcare, Inc. (NASDAQ:VMD) announced strong financial results for the third quarter ended September 30, 2025, with record net revenues of $71.9 million, a 24.0% increase year-over-year. The company reported a net income of $3.5 million ($0.09 per diluted share) and an Adjusted EBITDA of $16.1 million, while also updating its full-year 2025 guidance for net revenue and Adjusted EBITDA. Highlights include strategic acquisition of Lehan’s Medical Equipment, completion of its share repurchase program, and significant growth in ventilator and PAP therapy patient counts.
Viemed Healthcare, Inc. (NASDAQ:VMD) Short Interest Up 29.5% in March
Viemed Healthcare, Inc. (NASDAQ:VMD) experienced a significant 29.5% increase in short interest during March, reaching 450,066 shares, representing 1.5% of the company's shares. This surge in short interest comes after the company reported earnings that beat consensus estimates for EPS but fell slightly short on revenue. Amidst this, insiders, including President Michael Moore, sold shares totaling over $1.2 million in the last quarter, though insiders still retain a 20% ownership.
This Insider Has Just Sold Shares In Viemed Healthcare
Viemed Healthcare (NASDAQ:VMD) President Michael Moore recently sold shares worth US$1.2 million at an average price of US$9.05, representing 7.2% of his holding. While this was the largest insider sale in the last year for the company, it occurred at approximately the current share price, mitigating some concern. Insiders in Viemed Healthcare, which provides home medical equipment and respiratory healthcare services, hold 14% ownership, totaling about US$50 million, indicating a degree of alignment between management and shareholders despite no insider buying in the past year.
Viemed Healthcare Highlights Growth, Diversification and 2026 Guidance at Investor Conference
Viemed Healthcare (NASDAQ: VMD) presented its growth strategy, financial performance, and 2026 guidance at a recent investor conference. The company highlighted its strong financial momentum with a 26% CAGR since going public, $270M revenue in 2025, and a projected 2026 revenue of $310–$320M. Viemed is also diversifying its service offerings, with ventilation revenue decreasing from 87% to 48%, while sleep, oxygen, and other areas expand, addressing a large underserved market and benefiting from a favorable regulatory environment.
If You Invested $1,000 in Viemed Healthcare Inc (VMD)
This article analyzes the historical performance of Viemed Healthcare Inc (VMD) stock, detailing how a $1,000 investment would have fared over one, five, and ten years. It shows that while a $1,000 investment 10 years ago would now be worth $1,241, VMD has underperformed the S&P 500 by a significant margin over the same period. The article also provides an overview of Viemed Healthcare Inc, its business model focusing on in-home clinical care for respiratory conditions, its services, growth strategies including acquisitions, and financial disclosures.
Michael Moore Sells 65,000 Shares of Viemed Healthcare (NASDAQ:VMD) Stock
Viemed Healthcare President Michael Moore sold 65,000 shares of the company's stock on March 20th for $570,050, reducing his stake by almost 4%. This brings his total sales over three days to 136,802 shares. The company's stock, NASDAQ:VMD, traded at $8.71 with high volume, has a market cap of approximately $336 million, and analysts currently rate it as "Hold."
Viemed Healthcare (NASDAQ:VMD) President Sells $370,536.72 in Stock
Viemed Healthcare (NASDAQ:VMD) President Michael Moore sold 40,232 shares of the company's stock valued at $370,536.72, reducing his ownership by 2.38%. This sale was part of a series of transactions including additional sales on March 18th and 20th. Following these insider sales, the company's shares traded down 5.5% on increased volume, even though Viemed Healthcare recently reported earnings that beat analyst estimates but slightly missed revenue projections.
Viemed Healthcare (NASDAQ:VMD) President Michael Moore Sells 31,570 Shares
Viemed Healthcare (NASDAQ:VMD) President Michael Moore sold 31,570 shares of the company's stock on March 18th for approximately $297,389.40, reducing his ownership by 1.83%. This sale is part of a larger pattern of insider selling totaling 136,802 shares between March 18-20. The company's stock fell 5.5% to $8.71 on heavy volume, following recent mixed quarterly results and a "Hold" consensus rating from analysts, despite a "Strong-Buy" upgrade from one firm.
Viemed Healthcare president Moore sells shares worth $1.23m
Michael Moore, President of Viemed Healthcare, Inc. (NASDAQ:VMD), sold 136,802 common shares for approximately $1.23 million between March 18 and March 20, 2026. Despite these sales, Moore retains significant indirect and direct ownership in the company, which recently reported a Q4 2025 EPS beat but a revenue miss. InvestingPro analysis suggests the stock may be undervalued.
Viemed Healthcare (VMD) president’s LLC sells 136,802 common shares
Viemed Healthcare President Michael Moore reported indirect sales of 136,802 Common Shares through Moore Faster LLC between March 18 and March 20, 2026. The shares were sold at weighted-average prices ranging from $8.77 to $9.42, with each price representing multiple transactions. Following these sales, Moore Faster LLC holds 1,585,812 Common Shares indirectly, and Michael Moore directly holds 189,090 Common Shares.
Viemed Healthcare Insider Sold Shares Worth $1,237,976, According to a Recent SEC Filing
An insider at Viemed Healthcare, Inc. (VMD) sold shares valued at $1,237,976, according to a recent SEC filing. The article, published by MT Newswires, provides this financial transaction detail without further specifics on the insider or the nature of the sale. Viemed Healthcare is a provider of home medical equipment and post-acute respiratory healthcare services in the United States.
[144] VIEMED HEALTHCARE, INC. SEC Filing
Viemed Healthcare, Inc. (VMD) reported a Form 144 SEC filing, indicating a sale of 31,570 common shares by MOORE FASTER LLC on March 18, 2026, for proceeds of $297,345.20. The transaction was brokered by Morgan Stanley Smith Barney LLC. Both Rhea-AI and Capital Markets Analyst sentiments deemed the filing and its market impact as neutral, noting the routine nature and small size of the transaction relative to the market float.
VMD: Diversified home-based care platform posts record growth, driven by sleep and maternal health
Viemed Healthcare, Inc. (VMD) is experiencing rapid and profitable growth in its home-based care platform. This expansion is attributed to service diversification, technology adoption, and strategic M&A, with particular momentum in sleep, maternal health, and staffing divisions. Favorable regulatory conditions and reimbursement trends are further supporting the company's growth.
[144] VIEMED HEALTHCARE, INC. SEC Filing
This article provides details of a Form 144 SEC filing by Viemed Healthcare, Inc. (VMD) which indicates a proposed sale of 31,570 shares of common stock with an aggregate market value of $297,345.20. The securities were acquired on December 22, 2017, through a merger/acquisition, and the sale is being handled by Morgan Stanley Smith Barney LLC. The filing shows a neutral sentiment and is dated March 18, 2026.
Viemed Healthcare (VMD) grows to $270M revenue and guides up for 2026
Viemed Healthcare (VMD) reported strong 2025 financial results with $270 million in net revenue and $61 million in Adjusted EBITDA, marking its ninth consecutive year of positive net income. The company provided optimistic guidance for 2026, projecting net revenue between $310 million and $320 million, and Adjusted EBITDA between $65 million and $69 million. Viemed highlights its diversified, capital-light, home-based care model, with significant growth in its sleep therapy segment and a strong balance sheet supporting further expansion and shareholder returns.
Viemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
Viemed Healthcare, a national provider of home-based healthcare solutions, announced it will present and host one-on-one meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company, trading as NASDAQ:VMD, focuses on respiratory, chronic care, and women's health products and services. The presentation is scheduled for March 19 at 1:45 p.m. ET, and investors can register for the event and one-on-one meetings online.
Investors can stream Viemed’s Sidoti small-cap presentation free
Viemed Healthcare (NASDAQ: VMD) will present and host one-on-one investor meetings at Sidoti's Small-Cap Virtual Investor Conference on March 18-19, 2026. The company's presentation is scheduled for 1:45 p.m. ET on March 19, 2026, and registration for both the presentation and one-on-one meetings is free and open online. The announcement follows recent disclosures of record 2025 financial results and a new share repurchase program.
